KF0101

KF0101 is a **di-gold(I) organometallic complex** with the chemical structure [1,3-(Ph3PAu)2-C6H4], developed as an experimental anticancer agent. It has demonstrated cytotoxic activity in vitro, particularly against ovarian cancer cell lines, including those resistant to cisplatin. Notably, KF0101 exhibits little or no cross-resistance with cisplatin-resistant lines, implying a mechanism of action distinct from platinum drugs. Detailed studies using cell spectroscopy and cell-cycle analysis indicate KF0101 induces different cellular responses compared to standard chemotherapeutics like cisplatin and 5-fluorouracil, though its precise molecular targets remain undefined. Development appears to be at the preclinical/exploratory stage, and no evidence was found for clinical trials or commercial development by major pharmaceutical companies.[1][3][5]